COMP <GO>
CTSH vs VRSN // EV/EBITDA & P/E VALUATION
Cognizant Technology Solutions Corporation (NASDAQ) VS. VeriSign Inc. (NASDAQ) • 15-METRIC TALLY: CTSH 7
— VRSN 5
▲ EV/EBITDA & P/E VALUATION LEADER: CTSH
LAST: $65.11 (+4.14%) • MKT CAP: $28.16B
valuation
7.4x
LAST: $307.21 (+0.41%) • MKT CAP: $27.44B
valuation
25.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTSH VS. VRSN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTSH | VRSN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 19.60% | 40.30% | -20.70 | VRSN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.4x | 25.1x | -17.70 | CTSH | /valuation <GO> |
| Free Cash Flow Yield | 9.21% | 3.89% | +5.32 | CTSH | /fcf-yield <GO> |
| Operating Margin | 16.10% | 67.70% | -51.60 | VRSN | /operating-margins <GO> |
| Net Profit Margin | 10.60% | 49.80% | -39.20 | VRSN | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | 6.40% | +0.60 | CTSH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.17% | 0.78% | +1.39 | CTSH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.80 | 0.45 | +5.35 | CTSH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.1 | 56.6 | -9.50 | VRSN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.21 | -0.05 | VRSN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.7x | 30.9x | -19.20 | CTSH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $28.16B | $27.44B | $718.1M | CTSH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTSH REV | VRSN REV | CTSH GROSS % | VRSN GROSS % | CTSH FCF | VRSN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.11B | $1.66B | — | 88.2% | $2.60B | $1.07B |
| FY 2024 | $19.74B | $1.56B | — | 87.7% | $1.83B | $874.5M |
| FY 2023 | $19.35B | $1.49B | — | — | $1.46B | $786.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTSH // BETA 1.16
VRSN // BETA 1.21